Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Boston Scientific Acquires Elutia's Bioenvelope Products for $88 Million

Boston Scientific has entered into an agreement to acquire Elutia's bioenvelope product line for $88 million, marking a significant move in the cardiac rhythm management sector. The deal, expected to close in the fourth quarter of 2025, will see Boston Scientific take control of Elutia's Elupro and Cangaroo devices, designed to prevent complications following pacemaker or defibrillator implantation.

NoahAI News9/10/2025

California Invests $23.9M in Life Sciences to Boost Job Creation and Innovation in Los Angeles County

California has awarded $23.9 million in grants to four Los Angeles County life sciences projects, aiming to create 10,000 regional jobs by 2030 and position the area as a global leader in biotechnology innovation. The funding, announced by the Los Angeles County Department of Economic Opportunity, is part of a broader strategy to advance inclusive growth in the life sciences sector.

NoahAI News9/10/2025

FDA Approves Johnson & Johnson's Groundbreaking Bladder Cancer Treatment Inlexzo

The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's innovative bladder cancer treatment, Inlexzo, marking a significant advancement in the field of oncology. This drug-device combination offers new hope for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who have not responded to standard treatments and face the prospect of bladder removal.

NoahAI News9/10/2025

PMV Pharmaceuticals Reports Promising Results in Ovarian Cancer Trial, Plans FDA Filing

PMV Pharmaceuticals has announced encouraging interim results from its phase 1/2 trial of rezatapopt, a novel p53 reactivator, in ovarian cancer patients. The biotech company is now setting its sights on a potential FDA approval filing in early 2027, buoyed by a 43% response rate in the midphase study.

NoahAI News9/10/2025

Amgen's Diversified Portfolio Strategy Amid Obesity Drug Scrutiny

Amgen, a leading biotech company, is navigating a complex landscape of pharmaceutical development and market expectations. While its investigational obesity drug MariTide has garnered significant attention, the company is emphasizing a broader portfolio approach to drive future growth.

NoahAI News9/10/2025

Contingent Value Rights Gain Traction in Biotech Deals Amid Market Uncertainty

In an era of market volatility and heightened uncertainty in the biotech sector, companies are increasingly turning to contingent value rights (CVRs) to bridge valuation gaps and secure deals. This trend reflects the industry's efforts to maximize potential returns while mitigating risks in an environment where every dollar of value is crucial.

NoahAI News9/10/2025

Eli Lilly Launches AI-Powered Platform for Biotech Startups

Eli Lilly has unveiled a groundbreaking initiative aimed at accelerating drug discovery and development in the pharmaceutical industry. The company's new "TuneLab" platform will grant small biotechnology firms access to artificial intelligence (AI) models trained on Lilly's extensive research data, potentially revolutionizing the early stages of drug development.

NoahAI News9/10/2025

Novartis Ramps Up M&A Activity with Focus on Cardiovascular Pipeline

Novartis, the Swiss pharmaceutical giant, has been on a spending spree in 2025, solidifying its position as a major player in the cardiovascular disease market. The company's business development team has been particularly active, closing multiple deals worth a combined $17.23 billion in mergers, acquisitions, and licensing agreements this year alone.

NoahAI News9/10/2025

BMS and BioNTech's Pumitamig Shows Promise in Small Cell Lung Cancer

Bristol Myers Squibb (BMS) and BioNTech have reported encouraging results from a Phase II study of their investigational bispecific antibody, pumitamig (BNT327), in small cell lung cancer (SCLC). The data, presented at the 2025 World Conference on Lung Cancer, mark the first global readout for this anti-PD-L1/VEGF therapy and demonstrate consistent efficacy across different patient populations.

NoahAI News9/10/2025

LB Pharma Files for $228M IPO, Signaling Potential Thaw in Biotech Market

LB Pharma, a neuroscience-focused biotech company, has filed for an initial public offering (IPO) aiming to raise $228.5 million, marking a potential breakthrough in the long-dormant biotech IPO market. The company's bold move comes amid a challenging period for the sector, which has been experiencing what industry insiders call a "nuclear winter."

NoahAI News9/10/2025

Novartis Expands Cardiovascular Portfolio with $1.4B Acquisition of Tourmaline Bio

Novartis has announced its acquisition of New York-based biotechnology company Tourmaline Bio for $1.4 billion, marking a significant expansion of its cardiovascular disease pipeline. The deal, which is expected to close in the fourth quarter of 2025, centers around Tourmaline's promising anti-inflammatory drug pacibekitug.

NoahAI News9/10/2025

Regeneron's Allergy Antibodies Show Promise, but Market Potential Uncertain

Regeneron Pharmaceuticals has made significant strides in developing novel treatments for common allergies, with recent late-stage studies demonstrating the efficacy of their antibody combinations against cat and birch pollen allergies. However, industry analysts remain cautious about the commercial viability of these treatments in a market dominated by generic alternatives.

NoahAI News9/10/2025

«1...62 63 64...67 »